Clinical Trials
3 trialsNCT01623349 2021-02-10
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01068483 2020-12-08
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Novartis
Phase 1 Completed
NCT01363232 2020-10-05
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Array BioPharma
Phase 1 Completed